Icon Plc $ICLR Holdings Decreased by Swedbank AB

Swedbank AB trimmed its holdings in shares of Icon Plc (NASDAQ:ICLR) by 16.9% during the 1st quarter, Holdings Channel reports. The institutional investor owned 32,150 shares of the medical research company’s stock after selling 6,550 shares during the period. Swedbank AB’s holdings in Icon were worth $3,558,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the business. Toth Financial Advisory Corp acquired a new stake in Icon during the 4th quarter worth about $27,000. EFG International AG acquired a new position in shares of Icon in the 4th quarter valued at about $27,000. Abound Financial LLC purchased a new stake in shares of Icon in the fourth quarter worth approximately $54,000. Johnson Financial Group Inc. purchased a new stake in shares of Icon in the third quarter worth approximately $71,000. Finally, Blue Trust Inc. boosted its holdings in shares of Icon by 207.5% during the first quarter. Blue Trust Inc. now owns 658 shares of the medical research company’s stock worth $73,000 after purchasing an additional 444 shares during the period. 95.61% of the stock is owned by hedge funds and other institutional investors.

Icon Stock Down 0.6%

Shares of NASDAQ ICLR traded down $1.05 during trading hours on Friday, hitting $167.72. The stock had a trading volume of 308,538 shares, compared to its average volume of 912,130. The firm’s 50-day moving average price is $141.56 and its two-hundred day moving average price is $137.47. Icon Plc has a 52 week low of $66.57 and a 52 week high of $211.00. The company has a market capitalization of $12.84 billion, a P/E ratio of 29.84, a P/E/G ratio of 8.23 and a beta of 1.22. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.14 and a current ratio of 1.14.

Icon (NASDAQ:ICLR) last issued its quarterly earnings data on Tuesday, June 23rd. The medical research company reported $2.50 earnings per share for the quarter, beating the consensus estimate of $2.43 by $0.07. The firm had revenue of $2.03 billion for the quarter, compared to analyst estimates of $1.98 billion. Icon had a net margin of 5.35% and a return on equity of 8.73%. The company’s revenue for the quarter was up 2.5% on a year-over-year basis. During the same quarter last year, the firm earned $3.43 earnings per share. Analysts anticipate that Icon Plc will post 9.43 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on ICLR shares. Citigroup boosted their price objective on shares of Icon from $140.00 to $165.00 and gave the company a “neutral” rating in a research report on Thursday, June 25th. Robert W. Baird lifted their target price on shares of Icon from $168.00 to $186.00 and gave the company an “outperform” rating in a research note on Thursday, June 25th. Leerink Partners set a $145.00 price target on shares of Icon in a report on Thursday, May 28th. TD Cowen upped their price target on shares of Icon from $164.00 to $197.00 and gave the stock a “buy” rating in a research note on Thursday, June 25th. Finally, DA Davidson set a $164.00 price objective on Icon in a report on Monday, June 1st. Nine analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $173.19.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.